Arcutis Enrolls Last Patient in Phase II Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

Arcutis Biotherapeutics, Inc. announced it has completed enrollment of its Phase II proof of concept clinical trial evaluating roflumilast foam as a potential treatment for seborrheic dermatitis.
[Arcutis Biotherapeutics]
Press Release
Bookmark

No account yet? Register

0
Share

Dupixent® (Dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis

The National Medical Products Administration in China has approved Dupixent® for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
[Sanofi]
Press Release
Bookmark

No account yet? Register

0
Share

Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases

Sarepta Therapeutics, Inc. and Selecta Biosciences, Inc. announced that they have entered into a research license and option agreement granting Sarepta an option to license the rights to develop and commercialize Selecta’s immune tolerance platform for use in Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies.
[Sarepta Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases

Sarepta Therapeutics, Inc. and Codiak BioSciences, Inc. announced a global research and option agreement to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing and RNA technologies for neuromuscular diseases.
[Sarepta Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Bio-Techne and ZERO – The End of Prostate Cancer Announce Partnership to Fund Education and Awareness Campaigns to Empower Men with Prostate Cancer

Bio-Techne Corporation announced that Exosome Diagnostics has established a new partnership with ZERO – The End of Prostate Cancer.
[Bio-Techne Corporation]
Press Release
Bookmark

No account yet? Register

0
Share

Principia Presents Updated Positive Data of Rilzabrutinib for Immune Thrombocytopenia in Ongoing Phase I/II Trial

Principia Biopharma, Inc. announced positive data on durability of response from an ongoing Phase I/II trial of its investigational treatment, rilzabrutinib.
[Principia Biopharma, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

US Science Groups Wary of New Senate Bills to Curb Foreign Influences

A bipartisan group of US senators proposed sweeping—and controversial—changes in how the federal government manages academic research in the face of threats from other countries.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

0
Share

Emmes Announces Its Work on a Phase III Clinical Trial for Breakthrough Therapy Designation Product

Emmes announced that it provided the Phase III clinical trial support for a new investigational cell therapy that offers a promising treatment opportunity for patients who need an allogeneic bone marrow transplant.
[Emmes (PR Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Creatv Announces Ability to Predict Immunotherapy Treatment Response for Non-Small Cell Lung Cancer Using a Simple Blood Test

Creatv Microtech has pioneered a blood test to predict treatment response in patients with stage II-III NSCLC treated with chemoradiation therapy and consolidated immunotherapy.
[Business Wire, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology

Lassen Therapeutics announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and oncology.
[Lassen Therapeutics]
Bookmark

No account yet? Register

0
Share
Share